全文获取类型
收费全文 | 111篇 |
免费 | 4篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 12篇 |
妇产科学 | 3篇 |
基础医学 | 21篇 |
口腔科学 | 2篇 |
临床医学 | 6篇 |
内科学 | 18篇 |
皮肤病学 | 3篇 |
神经病学 | 3篇 |
特种医学 | 18篇 |
外科学 | 6篇 |
综合类 | 5篇 |
现状与发展 | 1篇 |
预防医学 | 7篇 |
眼科学 | 1篇 |
药学 | 7篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 1篇 |
2014年 | 5篇 |
2013年 | 5篇 |
2012年 | 3篇 |
2011年 | 6篇 |
2010年 | 10篇 |
2009年 | 5篇 |
2008年 | 3篇 |
2007年 | 2篇 |
2006年 | 4篇 |
2005年 | 4篇 |
2004年 | 2篇 |
2003年 | 4篇 |
2002年 | 3篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 7篇 |
1997年 | 8篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1975年 | 1篇 |
1959年 | 2篇 |
1941年 | 2篇 |
1939年 | 1篇 |
1936年 | 1篇 |
排序方式: 共有116条查询结果,搜索用时 15 毫秒
31.
32.
The Toll-like receptor adaptor protein MyD88 is essential for the regulation of intestinal homeostasis in mammals. In this study, we determined that Myd88-deficient mice are susceptible to colonic damage that is induced by dextran sulfate sodium (DSS) administration resulting from uncontrolled dissemination of intestinal commensal bacteria. The DSS-induced mortality of Myd88-deficient mice was completely prevented by antibiotic treatment to deplete commensal bacteria. By using cell type-specific Myd88-deficient mice, we established that B cell-intrinsic MyD88 signaling plays a central role in the resistance to DSS-induced colonic damage via the production of IgM and complement-mediated control of intestinal bacteria. Our results indicate that the lack of intact MyD88 signaling in B cells, coupled with impaired epithelial integrity, enables commensal bacteria to function as highly pathogenic organisms, causing rapid host death. 相似文献
33.
34.
35.
The survival motor neuron protein in spinal muscular atrophy 总被引:19,自引:1,他引:19
Coovert DD; Le TT; McAndrew PE; Strasswimmer J; Crawford TO; Mendell JR; Coulson SE; Androphy EJ; Prior TW; Burghes AH 《Human molecular genetics》1997,6(8):1205-1214
The 38 kDa survival motor neuron (SMN) protein is encoded by two
ubiquitously expressed genes: telomeric SMN (SMN(T)) and centromeric SMN
(SMN(C)). Mutations in SMN(T), but not SMN(C), cause proximal spinal
muscular atrophy (SMA), an autosomal recessive disorder that results in
loss of motor neurons. SMN is found in the cytoplasm and nucleus. The
nuclear form is located in structures termed gems. Using a panel of
anti-SMN antibodies, we demonstrate that the SMN protein is expressed from
both the SMN(T) and SMN(C) genes. Western blot analysis of fibroblasts from
SMA patients with various clinical severities of SMA showed a moderate
reduction in the amount of SMN protein, particularly in type I (most
severe) patients. Immunocytochemical analysis of SMA patient fibroblasts
indicates a significant reduction in the number of gems in type I SMA
patients and a correlation of the number of gems with clinical severity.
This correlation to phenotype using primary fibroblasts may serve as a
useful diagnostic tool in an easily accessible tissue. SMN is expressed at
high levels in brain, kidney and liver, moderate levels in skeletal and
cardiac muscle, and low levels in fibroblasts and lymphocytes. In SMA
patients, the SMN level was moderately reduced in muscle and lymphoblasts.
In contrast, SMN was expressed at high levels in spinal cord from normals
and non- SMA disease controls, but was reduced 100-fold in spinal cord from
type I patients. The marked reduction of SMN in type I SMA spinal cords is
consistent with the features of this motor neuron disease. We suggest that
disruption of SMN(T) in type I patients results in loss of SMN from motor
neurons, resulting in the degeneration of these neurons.
相似文献
36.
37.
38.
39.
SUMMARY: This report summarizes data for dialysis and transplant patients up to the end of 1995. We estimate coverage to be about 30% of dialysis patients and near complete ascertainment of transplant patients. On the 31 December 1995, there were 2224 patients on renal replacement therapy (RRT), comprising 50% on haemodialysis (HD), 12% on continuous ambulatory peritoneal dialysis (CAPD) and 38% with functioning transplants. the prevalence rate for dialysis was 68 per million population (p.m.p.) and that of transplant 42 p.m.p. the new dialysis acceptance rate was 15 p.m.p. and transplant 5 p.m.p. Forty-seven per cent of new patients had unknown primary renal disease and 30% was due to non-insulin dependent diabetes mellitus. Mean age of prevalent HD patients was 42 years, CAPD 46 years and 34 years for transplant. Patient survival on CAPD was 85% at 1 year and for HD was 88%. One year transplant patient survival was 94% and graft survival 91%. 相似文献
40.